Last deal

$4.6M

Amount

Series A

Stage

06.02.2014

Date

2

all rounds

$4.6M

Total amount

General

About Company
TNG Pharmaceuticals is developing FlyVax, a veterinary vaccine that inhibits horn flies.

Industry

Sector :

Subsector :

founded date

01.01.2011

Operating Status

Closed

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

FlyVax triggers an immune response that clots the blood at the wound, preventing horn flies from effectively feeding on cattle. This leads to lower infestations per cow, reducing stress and increasing weight and milk yield. TNG Pharmaceuticals, based in Louisville, KY, started at the University of Louisville's Entrepreneurship MBA program and has won multiple global business plan competitions.
Contacts

Phone number

Social url